Articles tagged "Antilymphocyte antibodies"

2018 American Transplant Congress
Survey of Rabbit Anti-Thymocyte Globulin Usage for Kidney Transplant Induction Therapy in the United States
K. Foster,¹ A. Dodson,² K. Gutierrez.²
¹Samford University McWhorter School of Pharmacy, Birmingham, AL; ²Comprehensive Transplant Institute, UAB Hospital, Birmingham, AL.
Background: Rabbit anti-thymocyte globulin (rATG) has become the most widely used induction agent in kidney transplantation (KTx) and has recently received FDA approval for this…
2018 American Transplant Congress
Outcomes Associated with Rabbit Anti-Thymocyte Globulin Induction According to Mg/Kg of Total Body Weight in Kidney Transplant Recipients
A. Brueckner, A. Logan, L. Bowman.
Pharmacy, Tampa General Hospital, Tampa, FL.
Purpose: The optimal dosing weight used for rabbit anti-thymocyte globulin (rATG) induction therapy in transplantation continues to lack a consensus. The impact of alternative dosing…
2017 American Transplant Congress
B Cell-Derived Cytokines Rather Than T/B Cognate Interactions Mediate CD8 T Cell Reconstitution Following Lymphoablation.
D. Zwick, K. Ayasoufi, R. Fan, V. Gorbacheva, K. Keslar, R. Fairchild, A. Valujskikh.
Immunology, Cleveland Clinic, Cleveland, OH
Antibody-mediated lymphoablation is a commonly used induction therapy in sensitized transplant recipients. Using murine anti-thymocyte globulin (mATG) in a model of BALB/c (H-2d) to B6…
2017 American Transplant Congress
Usefulness of Valacyclovir Prophylaxis for Preventing Cytomegalovirus Infection After Anti-Thymocyte Globulin Treatment as Antirejection Therapy.
E. Ko,^1,2 J. Yu,^1,2 B. Choi,^1,2 C. Park,^1,2 Y. Kim,^1,2 C. Yang,^1,2 B. Chung.^1,2
¹Transplant Research Center, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea; ²Division of Nephrology, Department of Internal Medicine, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea
Anti-thymocyte globulin (ATG) treatment for acute T-cell mediated rejection (TCMR) can increase the risk of CMV infection. We purposed to evaluate the effect of valacyclovir…
2017 American Transplant Congress
Using Basiliximab Does Not Increase De Novo DSA Incidence but Reduces Cytomegalovirus Infections and Neoplastic Complications in Non-Sensitized Kidney Transplant Patients.
M. Marron-Wojewodzki,¹ I. Szwarc,¹ C. Rene,² J.-F. Eliaou,² G. Mourad,¹ M. Le Quintrec.^1,3
¹Department of Nephrology, Dialysis and Transplantation, Hôpital Lapeyronie, Montpellier University Hospital, Montpellier, France; ²Departement of Immunology, Hôpital Saint Eloi, Montpellier University Hospital, Montpellier, France; ³Inserm U1183, IRMB, Hôpital Saint Eloi, Montpellier University Hospital, Montpellier, France
Background. In kidney transplantation, de novo donor specific antibodies (dnDSA) are associated with antibody-mediated rejection (AMR) and graft failure. After dnDSA development, 24% of the…
2017 American Transplant Congress
Biomarkers of Epithelial-Mesenchymal Transition (EMT) in Chronic Allograft Nephropathy: Potential for Early Detection and Development of Novel Therapeutic Agents.
S. Kanangat, R. Miller, S. Rezaeian, H. Eldib, D. Cimbaluk, C. Fhied, I. Kurbegovic-Skaljic, M. Prod, J. Borgia, M. Flaws, D. Castillo, R. DeCresce.
Pathology, BioChemistry and Medical Laboratory Sciences, Rush University Medical Center, Chicago, IL
Purpose: To detect markers and novel treatment targets related to fibrogenesis and eventual graft loss by focusing on Epithelial Mesenchymal transition (EMT) which requires understanding…
2016 American Transplant Congress
Impact of Early Red Blood Cell Transfusion After Kidney Transplantation on De Novo HLA Sensitization in the Setting of Antithymocyte Globulin Induction.
T. Jouve,^1,2 G. Rigault,^1,2 B. Janbon,¹ R. Tetaz,¹ N. Terrier,¹ D. Masson,³ L. Rostaing,^1,2 P. Malvezzi.¹
¹Nephrology and Kidney Transplantation Unit, Grenoble University Hospital, Grenoble, France, Metropolitan; ²Grenoble Alpes University, Grenoble, France, Metropolitan; ³Etablissement Francais du Sang, Grenoble, France, Metropolitan.
Introduction:HLA specific antibodies detection (HSA) and that of Donor Specific Antibodies (DSA) were revolutionized by the introduction of solid phase assays (Luminex®), therefore making these…
2016 American Transplant Congress
Clinical Factors That Determine the More Appropriate Induction Agent: ATG versus IL-2 Receptor Antagonists.
S. Bae, A. Massie, S. DiBrito, X. Luo, L. Kucirka, F. Al Ammary, D. Segev.
Johns Hopkins, Baltimore, MD.
Antithymocyte globulin (ATG) is recommended over IL-2 receptor antagonist (IL2) in high-risk recipients for induction immunosuppression. However, “high-risk” status has not been defined in an…
2016 American Transplant Congress
Outcomes in Elderly Renal Transplant Recipients Using Thymoglobulin or Interleukin-2 Receptor Antagonist Induction.
N. Jasiak,¹ J. Thielke,¹ J. Chen,² N. Hilal,¹ S. Salah,¹ D. Wu,¹ E. Benedetti,² P. West-Thielke.^1,2
¹Pharmacy, University of Illinois, Chicago; ²Transplant Surgery, University of Illinois, Chicago.
Background: Approximately 20% of all renal transplants performed in the US in 2014 occurred in elderly patients. Elderly patients are known to be at higher…
2016 American Transplant Congress
Outcomes in Obese Renal Transplant Recipients Using High versus Low-Dose Thymoglobulin.
N. Jasiak,¹ C. Stromayer,¹ J. Thielke,¹ J. Chen,² J. Chen,¹ B. Talon,¹ R. Rubin-Tobar,¹ E. Benedetti,² P. West-Thielke.^1,2
¹Pharmacy, University of Illinois, Chicago; ²Transplant Surgery, University of Illinois, Chicago, IL.
Background: Dosing of rabbit anti-thymocyte globulin (rATG) induction in renal transplant recipients is highly variable by transplant center. Optimizing rATG dose becomes extremely important for…